An observational study in Oral Nutritional Supplementation and Colon Cancer, sponsored by Osmaniye Korkut Ata University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Osmaniye Korkut Ata University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Colonic Neoplasms with a site in Turkey — 7 open to participants now, 11 under way, 2 of them phase 3. Colonic Neoplasms · Turkey.
Among the 29 studies in Colonic Neoplasms with a site in Turkey, this one is the 6th largest by enrollment of the 13 observational ones that give a count, is one of 6 that started in 2021, is one of 13 observational ones, and was the 28th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →7 of the 29 studies in Colonic Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Turkey, United States, Argentina and 26 more countries
Ages 18+
Cukurova University · Sites in Turkey
Ages 18–100
GlaxoSmithKline · Sites in Turkey, United States, Argentina and 25 more countries
Ages 18+
Kubra Sengor · Sites in Turkey
Ages 18–65 · Healthy volunteers
Acibadem University · Sites in Turkey
Ages 18–80
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3
First in 2013; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 209 is close to the median of 227 across 555 observational studies indexed under Colonic Neoplasms.
Median enrollment 83 across the 16 interventional studies, 140 across the 13 observational. Of the 14 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 29 have an industry lead sponsor. The 10 most frequent:
Osmaniye Korkut Ata University is the lead sponsor of 35 studies on the registry; 6 are open to participants now.
Osmaniye Korkut Ata University has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Colonic Neoplasms with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07205965Dokuz Eylul UniversityThe Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors | 2026-12-15 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Colonic Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This retrospective observational cohort study examined oral nutritional supplement (ONS) use and associated factors in patients receiving adjuvant mFOLFOX6 chemotherapy after curative surgery for stage III colon cancer. Medical and routine nutrition follow-up records from Osmaniye Training and Research Hospital between January 2021 and January 2026 were reviewed. The study included 362 patients prescribed ONS. The main outcomes were ONS non-initiation or early discontinuation and failure to meet a study-defined consumption criterion among ONS users. Demographic, clinical, nutritional, and psychosocial factors associated with these outcomes were evaluated.
Oral nutritional supplements (ONS) are prescribed to support nutritional intake when patients cannot meet their requirements through regular foods. However, prescribed supplements may not be initiated or consumed in the recommended amounts and duration. This single-center retrospective cohort study evaluated ONS consumption patterns and associated factors in adults with stage III colon adenocarcinoma receiving adjuvant mFOLFOX6 chemotherapy after curative surgery.
Data were obtained from electronic medical records, operative and pathology reports, oncology records, and routine Nutrition Outpatient Clinic forms for patients followed between January 2021 and January 2026. Eligible patients were aged 18 years or older, had been prescribed ONS during adjuvant chemotherapy, and had at least three months of clinical and nutritional follow-up with complete analytical data. No research-specific intervention or additional patient contact occurred.
Patients who never initiated ONS or used them for fewer than 7 days were classified as ONS non-users/early discontinuers. Patients who used ONS for at least 7 days were classified as ONS users. Among users, consumption of at least 75% of the recommended daily amount for at least 4 weeks was defined as meeting the study-specific consumption criterion. Consumption was assessed using patient-reported intake documented in routine follow-up records over approximately three months after prescription. Objective container counts or electronic consumption monitoring were not performed.
Recorded variables included demographic characteristics, living arrangements, comorbidities, surgical characteristics, postoperative complications, body mass index, Prognostic Nutritional Index, Nutritional Risk Screening 2002 scores, and Beck Depression Inventory scores. Reasons for ONS non-use, symptoms reported during ONS use, and attendance at dietitian follow-up visits were also evaluated.
Exploratory logistic regression analyses examined factors associated with non-initiation/early discontinuation among all eligible patients and failure to meet the consumption criterion among ONS users. Associations were interpreted as observational and did not establish causality.
Adults with histopathologically confirmed stage III colon adenocarcinoma who underwent curative surgery, received adjuvant mFOLFOX6 chemotherapy, and were prescribed ONS at Osmaniye Training and Research Hospital between January 2021 and January 2026.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with stage III colon cancer who were prescribed oral nutritional supplements (ONS) during adjuvant mFOLFOX6 chemotherapy after curative surgery but never initiated ONS or used them for fewer than 7 days, based on patient-reported consumption documented in routine nutrition follow-up records.
Patients with stage III colon cancer who were prescribed oral nutritional supplements (ONS) during adjuvant mFOLFOX6 chemotherapy after curative surgery and used them for at least 7 days, based on patient-reported consumption documented in routine nutrition follow-up records. These patients were further classified according to whether they consumed at least 75% of the recommended daily amount for at least 4 weeks.
Percentage of Patients With Oral Nutritional Supplement Non-Initiation or Early
Percentage of patients prescribed oral nutritional supplements (ONS) who never initiated use or used ONS for fewer than 7 days. The denominator includes all eligible patients prescribed ONS. Usage status was determined retrospectively from patient-reported consumption documented in routine nutrition follow-up records.
Time frame: From ONS prescription to approximately 3 months after prescription.
Percentage of Patients With Oral Nutritional Supplement Non-Initiation or Early Discontinuation
Percentage of patients prescribed oral nutritional supplements (ONS) who never initiated use or used ONS for fewer than 7 days. The denominator includes all eligible patients prescribed ONS. Usage status was determined retrospectively from patient-reported consumption documented in routine nutrition follow-up records.
Time frame: From ONS prescription to approximately 3 months after prescription.
Percentage of ONS Users Not Meeting the Study-Defined Consumption Criterion
Percentage of patients using oral nutritional supplements (ONS) for at least 7 days who did not meet the study-defined consumption criterion of consuming at least 75% of the recommended daily amount for at least 4 weeks. Failure to meet either threshold was classified as not meeting the criterion. The denominator includes patients who used ONS for at least 7 days. Consumption was assessed retrospectively using patient-reported intake documented in routine nutrition follow-up records.
Time frame: From ONS prescription to approximately 3 months after prescription.
Plan to share: No — Individual participant data will not be shared. This retrospective study used patient medical and nutritional follow-up records containing sensitive health information. Only aggregate study results will be disseminated to protect participant privacy and confidentiality.
Ran from Jan 2021 to primary completion in Jan 2026, 60 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Osmaniye Korkut Ata University